Bure Equity AB

Latest Results (03.07.2026):

Bure Equity AB — Q4 2024 (and full year 2024): In Q4 2024 Bure reports a year‑end net asset value (NAV) of SEK 333.0 per share (31 Dec 2024), a 29.1% increase for the full year 2024 from SEK 257.9 at the start of the year, though NAV fell 5.0% during Q4. Group earnings after tax for the year were SEK 5,735M (2024) and earnings per share were SEK 77.4. The Bure share total return for 2024 was 34.5% while the SIX Return Index rose 8.6%.

NAV & share performance

NAV per share was SEK 333.0 at 31 Dec 2024 (up 29.1% for 2024). NAV declined 5.0% during Q4 (from SEK 350.3). Report notes NAV of SEK 353.6 per share on 19 Feb 2025 (post‑period), +6.2% since the start of 2025.

Profit, EPS and value changes

Group earnings after tax were SEK 5,735M (2024). Fair value changes in financial assets drove most of the outcome (SEK ~5.6bn). Reported earnings per share were SEK 77.4 for 2024 (vs SEK 64.0 in 2023).

Top contributors to value growth

Listed holdings increased in value by SEK 5,795M to SEK 21,125M. Largest individual value drivers included Mycronic (+SEK 2,533M; ~39% share price gain in 2024) and Yubico (+SEK 2,061M; ~85% share price gain). Xvivo, Vitrolife and Cavotec also contributed materially.

Portfolio composition and activity

At year‑end listed holdings made up ~85.6% of NAV and unlisted ~11.4%. Key transactions: acquisition of 14.5% of Mentimeter for SEK 531M, purchase of 700,000 Cavotec shares (SEK 12M), Bure Growth’s convertible loan to BioLamina (SEK 17M) and other Atle‑related investments.

Unlisted, treasury and cash

Unlisted portfolio value rose by SEK 571M to SEK 2,826M. Treasury (cash, short‑term investments and other assets) fell by SEK 812M to SEK 738M (≈3.0% of NAV). The Group acquired financial assets totaling ~SEK 777M during the year.

Dividends, capital return and proposals

The Board proposes an ordinary dividend of SEK 2.75 per share for 2024 (versus SEK 2.50 for 2023). Bure reports having distributed and received dividends across the group; total dividends received were cited in the report.

Impairments, write‑downs and special items

Bure made a SEK 45M unconditional shareholder contribution to Mercuri, then wrote down the holding by SEK 79M to zero and increased a promissory note by SEK 13M. Other portfolio‑level impairments/revaluations are noted in the report.

Notable post‑period items & risks

Post‑period NAV improvement to SEK 353.6 (19 Feb 2025) was reported. Company highlights mention geopolitical/policy uncertainty (e.g., US administration changes and tariffs) as a risk to markets. Portfolio operational news included Yubico’s Nasdaq Main Market listing (Nov 2024) and ongoing regulatory/clinical steps for Xvivo (FDA application for a liver trial noted).